Phaseline

Companies › Neonc Technologies

Neonc Technologies: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NEO100 (perillyl alcohol)
Monoterpene with potential anti-tumor properties
–Phase 2Residual, Progressive or Recurrent Grade II or III Meningioma; Glioblastoma Multiforme; Pediatric Tumor of CNSNov 2026
NEO212
Covalent conjugate of temozolomide and perillyl alcohol (POH-TMZ)
MGMTPhase 1Diffuse Astrocytoma, IDH-MutantFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02704858NEO100 (perillyl alcohol)Phase 1Glioblastoma MultiformeOncologyNov 2026
NCT05023018NEO100 (perillyl alcohol)Phase 2Residual, Progressive or Recurrent Grade II or III MeningiomaOncologyDec 2026
NCT06047379NEO212Phase 1Diffuse Astrocytoma, IDH-MutantOncologyFeb 2027
NCT06357377NEO100 (perillyl alcohol)Phase 1Pediatric Tumor of CNSOncologyJun 2027

From the company's SEC filings

Cash of $6m on 2026-09-30; operating cash outflow about $23m a year; runway about 3 months at that burn, to Jan 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

MGMT (1)

Companies with the same targets

–

Companies built like this

Lantern Pharma Inhibrx Biosciences Immuneering Bio-Path Holdings ALX Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.